Spyre Therapeutics, Inc. (SYRE) insider trading

By person

7 insiders · 94 transactions

75.6×

Cameron Turtle holds 75.6 times base salary in stock. $50.30M of shares against $665.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Cameron Turtle last reported holding, valued at $93.57, the price Common Stock was last bought or sold at on the open market here, on 1 Oct 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Fairmount Funds Management LLC entity

Director

—

$399.66M (1) scheduled

−$399.66M

0.0000%

$0.00

−100.0%

Cameron Turtle

Chief Executive Officer

—

$10.32M (38) scheduled

−$10.32M

537,540

0.6096%

$50.30M

−28.1%

Scott L Burrows

Chief Financial Officer

—

$9.12M (26) scheduled

−$9.12M

79,762

0.0905%

$7.46M

−31.5%

Michael Thomas Henderson

Director

—

$7.95M (5) scheduled

−$7.95M

68,606

0.0778%

$6.42M

—

Sheldon Sloan

Chief Medical Officer

—

$7.35M (11) scheduled

−$7.35M

0.0000%

$0.00

—

Heidy King-Jones

See Remarks

—

$5.11M (10) scheduled

−$5.11M

2,845

0.0032%

$266.21K

0.0%

Jeffrey W. Albers

Director

—

$2.40M (3) scheduled

−$2.40M

9,360

0.0106%

$875.82K

−65.8%

Spyre Therapeutics, Inc.

What the insiders did Scheduled selling only

By person